Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levetiracetam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | CA12 | O43570 | 1/20 | 0.82 |
| ▸ | CA1 | P00915 | 1/20 | 0.82 |
| ▸ | CA2 | P00918 | 1/20 | 0.82 |
| ▸ | CA3 | P07451 | 1/20 | 0.82 |
| ▸ | CA4 | P22748 | 1/20 | 0.82 |
| ▸ | CA6 | P23280 | 1/20 | 0.82 |
| ▸ | CA5A | P35218 | 1/20 | 0.82 |
| ▸ | CA7 | P43166 | 1/20 | 0.82 |
| ▸ | CA9 | Q16790 | 1/20 | 0.82 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.82 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.82 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levitiracetam SCHEMBL61493 | 0.91 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL118843 | 0.91 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL373194 | 0.91 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL5072485 | 0.91 | LMNA (1.00) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL28457423 | 0.89 | LMNA (0.97) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL22031970 | 0.89 | LMNA (0.97) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL17372720 | 0.89 | LMNA (0.97) | LMNACA12CA1CA2CA3 | |
| Etiracetam SCHEMBL28026798 | 0.89 | LMNA (0.97) | LMNACA12CA1CA2CA3 | |
| Levetiracetam SCHEMBL6073150 | 0.86 | LMNA (0.90) | LMNACA12CA1CA2CA3 | |
| SCHEMBL660679 | 0.86 | LMNA (0.90) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118191155-A | Separation detection method of stereoisomer impurity in brivaracetam and preparation thereof | 上海市食品药品检验研究院 | 2024-06-14 | — | — | CN | disclosed |
| EP-3901137-B1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2023-01-25 | — | — | EP | disclosed |
| US-20220048856-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | SHANGHAI SYNCORES TECHNOLOGIES INC. LTD. (CN) | 2022-02-17 | — | — | US | disclosed |
| EP-3901137-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020125536-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | 浙江华海药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048856-A1 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | BLVRB, QDPR, CYP4B1 | LMNA 830/4885CA12 3695/4885CA1 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.